The US-based Generex Biotechnology Corporation, a company into new drug delivery systems and technologies, is planning to launch almost five new products in segments including diabetes and avian influenza in India through its partner within next six months.
The company, which has already launched its buccal insulin spray in collaboration with its exclusive partner - Mumbai-based Shreya Life Sciences Pvt Ltd - in India, is exploring options to launch its metformin chewing gum, avian influenza vaccine, glucose rapid spray and nicotin spray products in the country.
"We are interested to increase our activities in Asian market, and India offers an interesting market to our products on metabolic diseases. We will be introducing our metformin gum and glucose rapid spray in the country through Shreya," said Anna Gluskin, chair, president and chief executive officer, Generex Biotechnology Corporation. The company is also exploring opportunities to set up its office in India, she added.
The metformin chewing gum, which will deliver the diabetes drug covered with a gum, will attract the type-1 diabetics in particular though it has its effect on the type-2 diabetes patients too. The product will be available in various flavours including orange and pineapple and will be a prescription drug. The metformin chewing gum is currently at a late stage of development and will be ready to hit the market soon, averred Gluskin.
The company, in collaboration with Shreya, may soon launch its glucose rapid spray product to be used at the first sign of needing additional glucose in the patients' diet in India. Shreya will also market an avian influenza vaccine from Generex in the country, informed a higher source from Shreya Life Sciences Pvt Ltd.
In the second week of November, Shreya Life Sciences has launched the buccal insulin spray - Oral-Recosulin, developed with the support of Generex's technology - in the domestic market. The product, developed by Generex under the brand name Oral-lyn, is in the phase three global clinical trial. Generex is focusing on the Asian market for the product as the studies predict that the region will have the highest number of diabetes patients in 2025.
Generex Biotechnology Corporation, engaged in the research, development, and commercialization of drug delivery systems and technologies, has its own proprietary platform technology for the delivery of drugs into the human body through the oral cavity with no deposit in the lungs. The company has five to six products in its pipeline to address the diabetes, cardiovascular and obesity segments of therapeutics.